3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
ChronoScale Holdings completed the sale of its Ekso Bionics subsidiary on September 30, 2026, and said it will focus on its AI infrastructure business. On October 1, 2026, it also announced an expanded agreement with an existing AI infrastructure customer and a new customer agreement, which together with existing contracts provide for $1 billion in annualized revenue run rate by calendar Q3 2027. The filing does not disclose the sale price or the company's profit results, and the revenue run-rate is a non-GAAP measure subject to deployment and financing risks.
Sale of Ekso Bionics, Inc., a wholly owned subsidiary, completed September 30, 2026; the filing does not state the sale price
Expanded AI infrastructure customer agreement and new customer agreement, announced October 1, 2026, with combined contracts targeting $1 billion annualized revenue run rate by calendar Q3 2027
Chief Operating Officer of Ekso, Jason C. Jones, terminated effective September 30, 2026, with severance of $243,750 plus up to nine months of COBRA premiums
Series B Convertible Preferred Stock designation withdrawn September 29, 2026; no preferred shares were outstanding
Healthcare Triangle, Inc. received a Nasdaq Staff Delisting Determination because its closing bid price has been below $1.00 and the company is not eligible for a compliance period after cumulative reverse stock splits of 1-for-14,940 over two years. The company intends to request a Panel hearing, which would stay suspension, and its shares continue to trade as HCTI for now, but without a successful appeal the stock would be suspended from Nasdaq on October 12, 2026.
Nasdaq notice dated October 1, 2026 cites failure to meet the $1.00 minimum bid price under Rule 5550(a)(2)
Company is ineligible for a compliance period after a 1-for-249 reverse split (August 1, 2025) and a 1-for-60 reverse split (February 10, 2026)
Appeal to a Nasdaq Hearings Panel must be requested by October 8, 2026; otherwise trading suspension begins October 12, 2026
Company intends to request a hearing and may propose a reverse stock split; the Panel's outcome is not assured
On October 1, 2026, Tonix Pharmaceuticals received notice that Dr. Reddy's Laboratories had filed an ANDA with the FDA for a generic version of TONMYA, challenging four Orange Book patents. The filing matters to shareholders because it signals possible generic competition for TONMYA, and the company says it intends to vigorously enforce its intellectual property rights but cannot predict the outcome.
Notice received October 1, 2026 from Dr. Reddy's Laboratories Ltd. and Dr. Reddy's Laboratories, Inc.
ANDA covers a generic version of TONMYA (cyclobenzaprine hydrochloride) sublingual tablets, 2.8 mg, with a Paragraph IV certification
Certification targets U.S. Patent Nos. 9636408, 9956188, 10117936 and 10864175, all listed in the Orange Book
A patent infringement suit filed within 45 days of the notice would automatically block FDA approval of the ANDA for up to 30 months, subject to the outcome of litigation
Live Nation amended and restated CEO Michael Rapino's employment agreement, effective October 1, 2026, keeping him as President, CEO and board member through December 31, 2031. Base salary and target cash bonus are unchanged from his existing agreement, while the filing adds a $20 million upfront RSU grant and annual equity grants beginning in 2027.
Term runs from October 1, 2026 to December 31, 2031; agreement approved unanimously by the Board with Rapino abstaining
Base salary of $3,000,000 and target annual cash bonus of $17,000,000 (from 2027), same as the prior agreement
Upfront RSU grant of $20,000,000 on the Effective Date, plus annual grants of $10,000,000 in performance shares, $15,000,000 in time-based RSUs and $15,000,000 in target PSUs starting in 2027
Severance on termination without cause or for good reason is a lump sum equal to two times base salary, bonus and recent Annual Performance Shares value, plus full equity acceleration
Dragonfly Energy amended its senior secured term loan, with lenders waiving the minimum liquidity covenant test for the month ending September 30, 2026, and agreeing to waive any default tied to a deferred portion of the October 1, 2026 Series B preferred dividend. The company also agreed to a $450,000 amendment fee added to the loan principal, and the Series B holders waived their right to the full dividend on time, which means shareholders face a modified payment schedule and a larger loan balance.
Lenders waived testing of the minimum liquidity covenant solely for the fiscal month ending September 30, 2026.
The company will pay a $450,000 amendment fee, paid in kind by adding it to the outstanding Term Loan principal.
Series B holders waived the full October 1, 2026 dividend; the company must pay a 2% per annum cash dividend by October 1, 2026 and a 6% per annum cash dividend by October 30, 2026, with 2% per annum paid in kind.
Xcel Brands, Inc. received a letter from Nasdaq on September 29, 2026, saying its common stock closed below $1.00 per share for 30 consecutive business days, so it does not meet the minimum bid price requirement. The company has until March 29, 2027 to regain compliance, which requires a closing bid price of at least $1.00 for 10 consecutive business days; if it cannot, its shares could face delisting from the Nasdaq Capital Market.
Nasdaq notice dated September 29, 2026 cites a bid price below $1.00 for 30 consecutive business days.
Compliance period runs 180 calendar days, until March 29, 2027.
Regaining compliance requires a closing bid of at least $1.00 for 10 consecutive business days.
A reverse stock split may be needed; the company says there is no assurance it will regain compliance.
Gold.com entered into a Second Amended and Restated Credit Agreement with CIBC Bank USA as administrative agent on September 29, 2026. The uncommitted revolving line is payable on demand and is reduced from $427.5 million to $250 million, while many caps on dividends, buybacks, acquisitions and metals-related arrangements are removed or loosened.
Facility reduced from $427,500,000 to $250,000,000
Converted to an uncommitted revolving line of credit payable on demand
Caps on special and recurring dividends and share repurchases removed, subject to conditions
Agreement dated September 29, 2026; filed October 2, 2026
Verra Mobility's board appointed Jon Newhard as President and Chief Executive Officer, effective November 1, 2026, and as a director on the same date, which increases the board from six to seven members. He succeeds Jon Keyser, the interim CEO since June 2026, who will serve in an advisory role until December 31, 2026, while severance terms with Mr. Keyser are still being negotiated. The filing sets Mr. Newhard's base salary at $725,000 and includes a $4,750,000 inducement RSU award that remains subject to approval.
Jon Newhard, 57, was CEO of Yunex Traffic GmbH from March 2024 until September 2026 and previously led Clinc, Inc. and Cubic's ITS division.
Base salary of $725,000, with a target bonus of 100% of base salary and an estimated target equity grant date fair value of $4,000,000 beginning in fiscal 2027.
Inducement RSU award with a grant-date fair value of $4,750,000, subject to NASDAQ Listing Rule 5635(c)(4) approvals and vesting over three annual installments.
Jon Keyser remains in an advisory role until December 31, 2026, and the company is negotiating his severance arrangements.
BeyondSpring Inc. received a Nasdaq notice on September 29, 2026, stating its market value of listed securities has been below $35 million for 30 consecutive business days, so it no longer meets the continued listing requirement. The notice does not cause immediate delisting, and shares continue to trade on Nasdaq, but the company must regain compliance by March 29, 2027, or face a delisting process, which the company says it cannot assure.
Nasdaq notice received September 29, 2026 under Listing Rule 5550(b)(2)
Market value of listed securities fell below $35 million for 30 consecutive business days
Compliance period runs 180 calendar days, until March 29, 2027
Shares continue to trade on Nasdaq during the compliance period
Fog Cutter Holdings LLC bought the sponsor's shares and private units in Tavia Acquisition Corp. (TAVI) and took over sponsor duties, closing October 1, 2026. Andrew Wiederhorn, Chairman and CEO of Fog Cutter, became Executive Chairman and CEO, and Kenneth Kuick became CFO, as the board was reshaped.
Closing occurred October 1, 2026; Fog Cutter bought 2,243,333 ordinary shares and 249,107 private units from the sponsor
Sponsor retained 1,500,000 ordinary shares; Fog Cutter funds monthly trust contributions of up to $60,000 and operating expenses from October 1, 2026
Andrew Wiederhorn appointed Executive Chairman and CEO and Kenneth Kuick CFO, both effective October 1, 2026; three directors resigned September 28, 2026 and Askar Mametov resigned October 1, 2026
International Money Express refiled its antitrust notification under the HSR Act on October 2, 2026, because the original clearance expires one year after its waiting period ended. A new 30-day waiting period starts, and the California DFPI, which suspended its merger approval, is not expected to reinstate it before October 6, 2026. The Western Union merger remains pending and may take longer to close, which keeps shareholders waiting on the deal.
The original HSR waiting period expired at 11:59 p.m. Eastern Time on October 6, 2025, and clearance is effective for one year.
On October 2, 2026, the company and Western Union each filed HSR notification forms, starting a new 30-day waiting period; early termination was requested.
The DFPI suspended its approval of the merger, and the parties do not expect reinstatement before October 6, 2026.
Closing still requires the new HSR waiting period to expire or terminate, DFPI approval to be reinstated, and other closing conditions to be met.
Effective October 1, 2026, Jasper B. Sanfilippo, Jr. became chief executive officer, Jeffrey T. Sanfilippo moved to executive chair, and Frank Pellegrino was named president and chief financial officer. The filing also sets out Pellegrino's new pay package, which includes a higher base salary and additional equity awards, so the leadership change and its cost are relevant to shareholders.
Jasper B. Sanfilippo, Jr., previously chief operating officer, president and secretary, became CEO on October 1, 2026.
Jeffrey T. Sanfilippo, former CEO, became executive chair of the Board on October 1, 2026.
Pellegrino's base salary rose to $700,000 per year, with a target bonus of 100% of salary.
Pellegrino will receive a $600,000 annual equity award for fiscal 2027 plus a one-time $750,000 equity award.
On October 1, 2026, ESCO Technologies completed its purchase of all shares of Megger Group Limited from TBG AG for about $2.3 billion, paid in $922 million cash and 5.10 million shares of common stock. The company funded the cash portion and refinancing with about $1.0 billion borrowed under a new credit agreement, which replaced its existing credit agreement. Shareholders face higher debt and dilution from the new shares, and the seller gains a board seat right while it holds at least 50% of the consideration shares.
Purchase price of about $2.3 billion: $922 million in cash and 5.10 million shares of common stock, subject to a cash post-closing adjustment for net debt and working capital
New $1.5 billion credit facilities (revolver, Term Loan A and Term Loan B, $500 million each) became effective on the closing date, with about $1.0 billion borrowed
Existing credit agreement, scheduled to mature August 30, 2028, was terminated on the closing date
Board increased from eight to nine members; Jeremy P. Abson elected as a director effective October 1, 2026
Velo3D said Chief Financial Officer James Suva separated from the company on September 28, 2026, and that the separation was not due to any disagreement on operations, policies or practices. The board named Terence P. Wynn interim CFO and principal financial and accounting officer, serving through a services agreement with KongBasileConsulting LLC at $32,500 per month.
James Suva separated as CFO effective September 28, 2026; the filing states no disagreement with the company on operations, policies or practices.
Terence P. Wynn appointed Interim CFO effective September 28, 2026, as a consultant paid via KongBasileConsulting LLC, not as a company employee.
The Company will pay KBC a monthly fee of $32,500 for Mr. Wynn's services, prorated for partial months, plus pre-approved expenses.
KBC may terminate on at least 60 days' written notice; the Company may terminate at any time on written notice.
Grove Collaborative's Board appointed Flip van den Bosch, the company's Controller, as principal financial officer and principal accounting officer, effective October 1, 2026. The Compensation Committee approved a $25,000 retention bonus, a base salary increase to $261,397, and restricted stock units covering 30,000 Class A shares, which matter to shareholders as they set the pay terms for the company's senior finance role.
Flip van den Bosch, age 38, takes the principal financial officer and principal accounting officer roles effective October 1, 2026.
He has been Controller since March 2025 and has worked in the finance department since October 2022; previously he was at PricewaterhouseCoopers from September 2012 to October 2022.
Pay terms: $25,000 one-time cash retention bonus through May 15, 2027; base salary raised to $261,397 effective September 1, 2026; RSUs covering 30,000 shares vesting 15,000 on May 15, 2027 and 15,000 on August 15, 2027.
Flex Ltd. entered into a Credit Agreement dated September 29, 2026, providing a $3.3 billion senior term loan facility, with Citibank, N.A. as administrative agent. The facility was undrawn at closing and is intended in part to help fund the cash consideration for the acquisition of EPC Power Corp. and related assets, alongside cash on hand and other financing. Its availability reduces the company's existing $4.4 billion bridge facility dollar-for-dollar, and the filing contains covenants requiring a Debt/EBITDA ratio of no more than 4.50 to 1.00 and an Interest Coverage Ratio of at least 3.00 to 1.00.
Credit facility committed amount is $3.3 billion; it was not drawn on the September 29, 2026 closing date
Loans bear floating interest at Term SOFR or Base Rate plus an applicable margin tied to senior unsecured long-term debt ratings
Covenants require Debt/EBITDA of no more than 4.50 to 1.00 and Interest Coverage Ratio of at least 3.00 to 1.00
Effectiveness automatically and permanently reduced the commitments under the existing $4.4 billion 364-day bridge facility by the same amount
Snowflake completed a private offering of $3.75 billion in 0.00% convertible senior notes on September 28, 2026, comprising $2.0 billion due 2029 and $1.75 billion due 2031. The notes carry no regular interest, and holders may convert them into cash, shares, or a combination, at the company's election, which could lead to future dilution for shareholders, although capped call transactions are expected to reduce that potential dilution.
The 2029 notes mature October 15, 2029, with an initial conversion price of about $500.38 per share; the 2031 notes mature October 15, 2031, with an initial conversion price of about $483.98 per share.
Initial purchasers have options for up to an additional $300.0 million of 2029 notes and $250.0 million of 2031 notes.
Snowflake expects net proceeds of about $3.70 billion, with about $383.5 million used for capped call transactions and about $548.3 million for repurchasing about $261.8 million principal of its 2027 notes.
Star Holdings amended its term loan with Safehold, extending maturity to March 31, 2029, and amended its management agreement with a Safehold subsidiary, raising the termination fee to $62.5 million. On September 30, 2026, the company also cut its margin loan balance from $94.5 million to $46.5 million, which reduces its borrowing but adds fee costs that shareholders should weigh.
Margin loan balance reduced from $94.5 million to $46.5 million on September 30, 2026, funded mainly by about $30.0 million of asset sale proceeds and $18.0 million of restricted cash
Term loan maturity extended one year to March 31, 2029, with an extension fee of 0.5% of outstanding loans and a 1.0% per annum rate increase during any extension to September 30, 2029
Management agreement termination fee increased from $55.0 million to $62.5 million, with minimum quarterly management fees of $1.25 million and $625,000 set for later annual terms
Solesence, Inc. received a Nasdaq notice on September 29, 2026 stating its stock closed below $1.00 per share for 30 consecutive trading days, so it no longer meets Nasdaq's minimum bid price rule. The notice has no immediate effect on the stock's listing, but the company must regain compliance by March 29, 2027, or face possible delisting, and it says there is no assurance it will do so.
Nasdaq notice dated September 29, 2026; stock below $1.00 for 30 consecutive trading days
Initial compliance period of 180 calendar days, ending March 29, 2027
To regain compliance, closing bid must be at or above $1.00 for at least 10 consecutive trading days before March 29, 2027
Company may get an additional 180-day grace period if it meets listing criteria and notifies Nasdaq of its intent to cure
MacKenzie Realty Capital, Inc. temporarily suspended its preferred Dividend Reinvestment Program (DRIP) and its preferred share repurchase program while it reviews strategic alternatives brought by its financial advisor, Maxim Group LLC. The pending October dividend will be paid fully in cash, including to holders who had elected DRIP participation, and the Board approved regular preferred dividends for the quarter ending December 31, 2026, at the same amounts as previous quarters. Preferred holders lose the reinvestment and repurchase options for now, and the company states there is no assurance that any strategic transaction will result.
DRIP suspended for this cycle; the October dividend is paid entirely in cash, including to enrolled DRIP participants, per the October 2, 2026 letter.
Preferred share repurchase program temporarily suspended while the company reviews strategic alternatives from Maxim Group LLC; the company says there can be no assurance of a strategic transaction.
Board approved monthly dividends of $0.125 per Series A share, $0.0625 per Series B share and $0.1875 per Series C share for holders of record on October 31, November 30 and December 31, 2026, payable in January 2027.
DRIP intended to resume after the SEC qualifies the amended Offering Circular, with no new election required from enrolled participants.
Mercer International said a special committee is in advanced talks with holders of more than 75% of its 2028 and 2029 senior notes on a comprehensive recapitalization and capital infusion. The company elected not to make a $25.8 million interest payment due October 1, 2026 on the 2028 notes and is using the indenture's 30-day grace period, which it says is not an event of default.
Missed interest payment of approximately $25.8 million on 12.875% 2028 Senior Notes was due October 1, 2026; company is using 30-day grace period
Ad Hoc Group holds more than 75% of the aggregate principal of the 2028 and 5.125% 2029 Senior Notes
Company is optimistic about announcing a Transaction in the near term but gives no assurance of a definitive agreement or its timing or terms
On October 1, 2026, holders of a majority of Hub Group's voting power, including Yeager family trusts, acted by written consent to remove three directors, appoint four new directors, and adopt Second Amended and Restated Bylaws. Three other directors resigned the same day, and the company says David P. Yeager remains Chairman and CEO. The changes come while Hub Group works to complete a restatement and file delayed periodic reports and faces a Nasdaq delisting process with a hearing set for October 27, 2026.
Michael Flannery, Peter McNitt, and Gary Yablon were removed as directors without cause, effective October 1, 2026.
Gregory D. Bunch, Thomas P. Fitzgerald, Thaddeus J. Malik, and Thomas M. White were appointed as directors, effective October 1, 2026.
Mary H. Boosalis, Jenell Ross, and Martin P. Slark resigned from the Board, effective October 1, 2026.
Nasdaq issued a Staff Delisting Determination on September 16, 2026; the company has appealed, and the Nasdaq Hearings Panel hearing is scheduled for October 27, 2026, with the delisting stayed pending the outcome.
Integra LifeSciences released preliminary third-quarter 2026 results and lowered its full-year 2026 revenue and adjusted EPS guidance after July flooding at its Cincinnati manufacturing facility. The company says the flood reduced third-quarter revenue by about $7 million and will reduce fourth-quarter revenue by $15 million to $20 million, and it expects insurance to offset a substantial portion of the earnings impact.
Third-quarter revenue expected at $410 million to $412 million, with adjusted EPS of $0.55 to $0.59; results are unaudited and subject to closing procedures.
Full-year 2026 revenue outlook lowered to $1.634 billion to $1.654 billion from $1.654 billion to $1.695 billion; adjusted EPS guidance lowered to $2.30 to $2.40 from $2.40 to $2.50.
Full-year 2026 operating cash flow expected at about $190 million to $200 million, and greater than $85 million in the third quarter.
Full manufacturing operations at the Cincinnati facility are expected to return during the second quarter of 2027.
Surrozen said the FDA cleared its Investigational New Drug application for SZN-8141, a treatment for diabetic macular edema, allowing clinical development to advance. The clearance satisfies a milestone for the second closing of its March 2025 private placement, which is expected to bring about $95.1 million in gross proceeds on or about October 20, 2026, before placement agent fees and other expenses.
FDA clearance of the SZN-8141 IND took effect after the statutory 30-day review period, announced October 2, 2026
First patient dosing in the Phase 1b/2a DUET study is expected in Q4 2026, with initial data expected in 2H 2027
Second closing of the March 2025 two-tranche private placement expected on or about October 20, 2026, with approximately $95.1 million in gross proceeds
Surrozen must file a Form S-3 resale registration statement within 30 calendar days after the closing
EchoStar disclosed that its DISH DBS filing entities emerged from Chapter 11 bankruptcy on the Effective Date under a prepackaged plan and restructuring support agreement. The company said the entities will be reconsolidated into its financial statements as of that date, after they were deconsolidated effective June 30, 2026. The filing also covers supplemental indentures to three DISH DBS note indentures, with full copies to be filed with the next Form 10-Q.
DISH DBS entities entered supplemental indentures on October 1, 2026 covering 5.25% and 5.75% senior secured notes, 7.375% senior notes due 2028, and 5.125% senior notes due 2029.
DISH DBS filing entities were deconsolidated effective June 30, 2026, and will be reconsolidated as of the Effective Date.
Financial statements of DISH DBS will be filed by amendment no later than 71 calendar days after the 8-K due date.
United States Antimony Corp (UAMY) appointed Shawn Winkler as permanent Senior Vice President and Chief Financial Officer effective September 30, 2026, after he served as interim CFO since May 4, 2026. The Board also terminated former CFO Richard Isaak's employment without cause, effective the same date, and the company said the termination was not related to its financial or operating results or to any concerns about its financial or reporting practices.
Shawn P. Winkler appointed permanent SVP and CFO effective September 30, 2026; he was interim CFO from May 4, 2026
Richard R. Isaak ceased to be SVP and CFO and his employment was terminated without cause, effective September 30, 2026
Winkler previously was CFO of Burrow Global and spent 15 years as an investment banker at BMO Capital Markets and Deutsche Bank Securities
ACCO Brands said on October 2, 2026 that it has completed its previously announced acquisition of GXT Holding B.V., together with its subsidiaries, also known as Trust. Trust designs and markets PC accessories, gaming, smart home and mobile peripherals across Europe and Latin America. The filing does not disclose the purchase price or any financial results, so shareholders cannot yet gauge the deal's size or effect on earnings from this disclosure alone.
Acquisition of GXT Holding B.V. (Trust) completed, announced October 2, 2026
Trust sells through leading retailers, e-commerce platforms and B2B channels in Europe and Latin America
The filing does not state the purchase price or financial terms of the deal
On October 1, 2026, CareTrust completed the purchase of 24 completed UK care homes from LNT Care Developments for £576 million (about $764 million), excluding transaction costs. The company also expects to acquire 21 more homes under development for £504 million (about $669 million) on a rolling basis through December 31, 2027, and raised its full-year 2026 guidance, which shareholders may view as a sign of improved earnings expectations.
24 completed care homes acquired October 1, 2026 for £576 million (about $764 million), excluding transaction costs
21 in-development homes to be acquired for £504 million (about $669 million) as they are completed and approved, through December 31, 2027
Full-year 2026 guidance raised: net income attributable to CareTrust of $1.54 to $1.57 per share and Normalized FFO of $2.06 to $2.09 per share
Initial closing funded by proceeds from settling outstanding forward equity agreements and a draw on the revolving credit facility
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.